Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure. The company also markets Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. In addition, it develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VCEL
CUSIPN/A
Phone800-556-0311
Debt
Debt-to-Equity Ratio0.16
Current Ratio7.72
Quick Ratio7.48
Price-To-Earnings
Trailing P/E Ratio-24.15
Forward P/E Ratio-34.12
P/E GrowthN/A
Sales & Book Value
Annual Sales$63.92 million
Price / Sales7.75
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book17.85
Profitability
EPS (Most Recent Fiscal Year)($0.50)
Net Income$-17,280,000.00
Net Margins-23.35%
Return on Equity-37.86%
Return on Assets-21.19%
Miscellaneous
Employees205
Outstanding Shares42,730,000
Market Cap$551.17 million
Vericel (NASDAQ:VCEL) Frequently Asked Questions
What is Vericel's stock symbol?
Vericel trades on the NASDAQ under the ticker symbol "VCEL."
How were Vericel's earnings last quarter?
Vericel Corp (NASDAQ:VCEL) released its quarterly earnings data on Monday, August, 6th. The biotechnology company reported ($0.12) EPS for the quarter, hitting analysts' consensus estimates of ($0.12). The biotechnology company had revenue of $19.01 million for the quarter, compared to the consensus estimate of $18.51 million. Vericel had a negative return on equity of 37.86% and a negative net margin of 23.35%. View Vericel's Earnings History.
When is Vericel's next earnings date?
What price target have analysts set for VCEL?
5 Wall Street analysts have issued 1-year price objectives for Vericel's stock. Their forecasts range from $14.00 to $17.00. On average, they anticipate Vericel's share price to reach $15.00 in the next year. This suggests a possible upside of 29.3% from the stock's current price. View Analyst Price Targets for Vericel.
What is the consensus analysts' recommendation for Vericel?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vericel.
Who are some of Vericel's key competitors?
Some companies that are related to Vericel include Spark Therapeutics (ONCE), Acceleron Pharma (XLRN), Regenxbio (RGNX), Repligen (RGEN), Momenta Pharmaceuticals (MNTA), Rubius Therapeutics (RUBY), Atara Biotherapeutics (ATRA), Sangamo Therapeutics (SGMO), Denali Therapeutics (DNLI), Editas Medicine (EDIT), Iovance Biotherapeutics (IOVA), Solid Biosciences (SLDB), Audentes Therapeutics (BOLD), Coherus Biosciences (CHRS) and Acorda Therapeutics (ACOR).
Who are Vericel's key executives?
Vericel's management team includes the folowing people:
- Mr. Dominick C. Colangelo, CEO, Pres & Director (Age 54)
- Mr. Gerard J. Michel, CFO & VP of Corp. Devel. (Age 55)
- Mr. Daniel R. Orlando, Chief Operating Officer (Age 53)
- Ms. Jacquelyn Fahey Sandell, VP, Gen. Counsel & Corp. Sec.
- Ms. Heidi Hassen, Sr. Director of HR
Has Vericel been receiving favorable news coverage?
Press coverage about VCEL stock has trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vericel earned a media and rumor sentiment score of 0.14 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 47.78 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for Vericel.
Who are Vericel's major shareholders?
Vericel's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.05%), RTW Investments LP (5.19%), Millennium Management LLC (1.86%), Castleark Management LLC (1.69%), First Washington CORP (1.54%) and Renaissance Technologies LLC (1.48%). Company insiders that own Vericel stock include Alan L Rubino, Daniel Orlando, Dominick Colangelo and Paul K Wotton. View Institutional Ownership Trends for Vericel.
Which institutional investors are selling Vericel stock?
VCEL stock was sold by a variety of institutional investors in the last quarter, including EAM Investors LLC, PNC Financial Services Group Inc., Renaissance Technologies LLC, GSA Capital Partners LLP and Algert Global LLC. Company insiders that have sold Vericel company stock in the last year include Daniel Orlando, Dominick Colangelo and Paul K Wotton. View Insider Buying and Selling for Vericel.
Which institutional investors are buying Vericel stock?
VCEL stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Acadian Asset Management LLC, Mutual of America Capital Management LLC, Emerald Mutual Fund Advisers Trust, United Services Automobile Association, Granahan Investment Management Inc. MA, Acuta Capital Partners LLC and Redmile Group LLC. View Insider Buying and Selling for Vericel.
How do I buy shares of Vericel?
Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vericel's stock price today?
One share of VCEL stock can currently be purchased for approximately $11.60.
How big of a company is Vericel?
Vericel has a market capitalization of $551.17 million and generates $63.92 million in revenue each year. The biotechnology company earns $-17,280,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Vericel employs 205 workers across the globe.
How can I contact Vericel?
Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 800-556-0311 or via email at [email protected]
MarketBeat Community Rating for Vericel (NASDAQ VCEL)
MarketBeat's community ratings are surveys of what our community members think about Vericel and other stocks. Vote "Outperform" if you believe VCEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
